The Medical Letter on Drugs and Therapeutics
Correction: Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

In our June 13, 2011 article (Med Lett Drugs Ther 2011; 53:46), we said that the FDA has approved Nuedexta for treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). That is not quite correct. The package insert says that the drug is indicated for the treatment of pseudobulbar affect and then goes on to say, in the next two sentences, that studies to support the effectiveness of Nuedexta were performed in patients with underlying ALS or MS, and that the drug has not been shown to be safe or effective in other types of emotional lability. Also, the second sentence in the Drug Interactions paragraph should have said: "Other drugs that prolong the QT interval, inhibit CYP3A4, or are metabolized by CYP2D6 and prolong the QT interval, should be used with caution, if ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Correction: Dextromethorphan Quinidine (Nuedexta) for Pseudobulbar Affect
Article code: 1368d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian